Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies

"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

The data are to be presented at an upcoming medical conference.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The Oncologic Drugs Advisory Committee meeting is scheduled for May 21, 2025.

The sBLA for NAI was submitted to the FDA in March 2025.